Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYR-322 alone and with pioglitazone for postprandial lipids in type 2 diabetes
NL-OMON32102Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Placebo, SYR-322 and SYR-322 + pioglitazone (3 arms). Primary endpoint: Change from baseline in postprandial incremental area under the curve for triglycerides at Week 16. Started Aug 2008; status: active, not recruiting.
02
Drugs
alogliptinpioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON32102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32102.